Hu Lan, Jin Hua, Li Xu, Hu Qin, Zhang Xuelian
First School of Clinical Medicine, Anhui University of Chinese Medicine, Hefei, China.
Department of Nephrology, The First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, China.
Ren Fail. 2025 Dec;47(1):2538801. doi: 10.1080/0886022X.2025.2538801. Epub 2025 Sep 10.
Histone methylation (HMT), the enzymatic addition of methyl groups to specific histone residues by histone methyltransferases, constitutes a key regulatory mechanism in gene expression and post-translational modulation. Although studies have explored HMT's role in oncogenesis and other organ-specific disorders, HMT is now implicated in the pathogenesis of kidney diseases. A broad spectrum of experimental models, including both and systems, has demonstrated the involvement of HMT alterations in diverse renal pathologies such as acute kidney injury, renal fibrosis, diabetic nephropathy, lupus nephritis, polycystic kidney disease, kidney stones, renal cell carcinoma, and immunoglobulin A nephropathy. Targeted modulation of HMT has been associated with attenuated disease progression across these conditions. This review synthesizes current insights into HMT's mechanistic roles in renal pathology and delineates its therapeutic potential as a strategic intervention in kidney disease management.
组蛋白甲基化（HMT）是指通过组蛋白甲基转移酶将甲基基团酶促添加到特定组蛋白残基上，它构成了基因表达和翻译后调控中的关键调节机制。尽管已有研究探讨了HMT在肿瘤发生和其他器官特异性疾病中的作用，但HMT现在也与肾脏疾病的发病机制有关。包括体内和体外系统在内的广泛实验模型已证明，HMT改变参与了多种肾脏病理过程，如急性肾损伤、肾纤维化、糖尿病肾病、狼疮性肾炎、多囊肾病、肾结石、肾细胞癌和免疫球蛋白A肾病。在这些疾病中，对HMT进行靶向调节与疾病进展减缓相关。本综述综合了目前对HMT在肾脏病理中的机制作用的见解，并阐述了其作为肾脏疾病管理中的一种战略干预措施的治疗潜力。
